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Systemic lupus erythematosus is a potentially fatal
autoimmune disease. Although interleukin-17 (IL-
17) has been linked to human lupus and mouse
models of this disease, it has not been addressed
whether this cytokine plays a critical role in fatal
lupus pathology. Here we have demonstrated that
increased production of IL-17 cytokines and their
signaling via the adaptor protein CIKS (a.k.a.
Traf3ip2, Act1) critically contributed to lethal pathol-
ogy in an FcgammaR2b-deficient mouse model of
lupus. Mice lacking IL-17 and especially those lack-
ing CIKS showed greatly improved survival and
were largely protected from development of glomer-
ulonephritis. Importantly in this model, potential
effects of IL-17 cytokines on antibody production
could be distinguished from critical local contribu-
tions in kidneys, including recruitment of neutrophils
and monocytes. These findings provide the proof of
principle that signaling by IL-17 family cytokines
mediated via CIKS presents promising therapeutic
targets for the treatment of systemic lupus erythema-
tosus, especially in cases with kidney involvement.
INTRODUCTION
Systemic lupus erythematosus (SLE) is one of the most common
and devastating systemic autoimmune diseases. In health,
various tolerance mechanisms prevent the generation of autor-
eactive B cells, but once these mechanisms are breached,
autoantibodies may be produced, causing immune complex
deposition and inflammation. Unless SLE patients receive effec-
tive therapies, chronic activation of the immune system and local
inflammation may cause permanent organ damage, including
glomerulonephritis, leading to renal failure and death.
To elucidate mechanisms underlying the pathogenesis of SLE,
we investigated Fcgamma receptor II-b (Fcgr2b)-deficient mice
(generated with 129 embryonic stem cells [ESCs], extensively
backcrossed to C57BL/6), which develop a fatal lupus-like
disease (Bolland andRavetch, 2000; Dae¨ron et al., 1995). Fcgr2b1104 Immunity 37, 1104–1115, December 14, 2012 ª2012 Elsevier Inhas been identified as a lupus susceptibility gene in both humans
and mice. This inhibitory receptor is thought to help maintain
tolerance mechanisms that prevent formation of autoantibody-
producing B cells and restrain inflammation in response to
immune complex deposition (Baerenwaldt et al., 2011; Smith
and Clatworthy, 2010). 129-derived gene variants immediately
surrounding the deleted Fcgr2b locus in this mouse background
are likely to also play a role in the breach in tolerance, consistent
with the multigenic nature of lupus (Boross et al., 2011; Harley
et al., 2008; Sato-Hayashizaki et al., 2011).
Interleukin-17 (IL-17, a.k.a. IL-17A) is the signature cytokine
of T helper-17 cells, and these cells also produce the closely
related IL-17F; both cytokines have been linked to the develop-
ment of various autoimmune diseases, including multiple
sclerosis (MS), rheumatoid arthritis (RA), and SLE. Patients
with these diseases express increased amounts of IL-17A
and IL-17F (Doreau et al., 2009; Matusevicius et al., 1999; Ziol-
kowska et al., 2000). Furthermore, IL-17A and IL-17F have
been shown to be functionally relevant in the pathogenesis of
collagen-induced arthritis (CIA) and experimental autoimmune
encephalomyelitis (EAE) in mice; in addition, IL-17C is involved
in psoriasis and may also contribute to other diseases, including
EAE (Chang et al., 2011; Komiyama et al., 2006; Nakae et al.,
2003; Ramirez-Carrozzi et al., 2011). IL-17A, IL-17F, and
IL-17C are members of an extended family of IL-17 cytokines
(A–F) that signal via heteromeric receptors composed of
members of the IL-17 receptor family (RA–RE) (Gaffen, 2009).
CIKS (a.k.a. Traf3ip2 or Act1) is an adaptor protein required for
signaling by these cytokines (Chang et al., 2011; Gaffen, 2009).
Consistent with a role for IL-17 cytokines in disease, the CIKS
(Traf3ip2; Act1) adaptor is essential for development of CIA
and EAE (Pisitkun et al., 2010; Qian et al., 2007).
Recombinant inbred BXD2 mice develop erosive arthritis and
a lupus-like condition. Loss of Il17ra, a receptor chain required
for signaling by IL-17 cytokines, abrogates spontaneous
germinal center formation in this mousemodel, whereas addition
of IL-17 exacerbates this process (Hsu et al., 2008). IL-17 also
synergizes with ‘‘B cell activating factor belonging to the TNF
family’’ to promote the survival and/or proliferation of human B
cells and their differentiation into antibody secreting cells
in vitro (Doreau et al., 2009). These findings suggest possible
roles for IL-17 in autoantibody production; however, it has not
been addressedwhether such contributions are actually relevantc.
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Figure 1. Loss of the IL-17 Signaling Adaptor CIKS Improves Survival of Fcgr2b–/– Mice
(A) Cells from spleen and lymph node (LN) of WT and Fcgr2b/mice (6–8 months old) were gated on CD3+ and stained for intracellular expression of IL-17A and
IL-17F. A profile representative of five mice per group is shown.
(B) Percentage of IL-17A and F producing T cells in spleen and LN (n = 5–7).
(C and D) Percentage of CD3+ T subsets in spleen (n = 5–9) and LN (n = 10–16). DN-T cells are CD3+CD4CD8.
(E and F) Percentage and numbers of IL-17 producing CD3+ T subsets in spleen (n = 4–7) and LN (n = 7–10). (*p < 0.05, **p < 0.01, ***p < 0.001; mean ± SEM).
(G) Cumulative survival of Fcgr2b/.Traf3ip2+/mice (n = 13) and Fcgr2b/.Traf3ip2/mice (n = 12); (***p < 0.001). Percent survival rate change = ([% survival
of Fcgr2b/.Traf3ip2/ % survival of Fcgr2b/.Traf3ip2+/] /% survival of Fcgr2b/.Traf3ip2/) 3 100 = ([75  7.7]/75) 3 100 = 89.7%.
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Roles of IL-17 Cytokines in Lupus Nephritisfor the fatal outcome in the BXD2 mouse model. Other studies
have provided evidence for increased amounts of IL-17 in
kidneys of SLE patients and Mrl/lpr and BL6/lpr lupus-prone
mice and for a functional role of IL-23 in the latter model (Crispı´n
et al., 2008; Kyttaris et al., 2010). These findings suggest involve-
ment of T helper 17 (Th17) cells and/or IL-17 cytokines in kidney
pathology, but it has not been addressed whether IL-17 cyto-
kines are in fact functionally relevant in development of fatal
kidney disease in mouse models for lupus.
Here we demonstrate that CIKS (Traf3ip2) adaptor-mediated
signaling from IL-17 cytokines, including IL-17A and likely also
IL-17C, plays a major role in the development of fatal lupus
pathology in Fcgr2b/ mice. Loss of CIKS, which blocks sig-
naling by all IL-17 cytokines, and to a lesser extent loss of
IL-17A, significantly reducedmortality rates, specifically protect-
ing mice from glomerulonephritis, by eliminating an important
pathway for chemokine-mediated recruitment of inflammatory
cells into kidneys, in particular neutrophils. Contributions of
IL-17 cytokines to end-organ pathology were crucial for progres-
sion of the disease, and without these contributions autoanti-
bodies alone were largely insufficient to cause severe kidneyImmpathology. Consistent with this, signaling of these cytokines
into B cells did not significantly contribute to the course of
glomerulonephritis in Fcgr2b/ mice. Importantly, we detected
neutrophil extracellular traps (NETs) in kidneys of Fcgr2b/
mice, but not in the absence of IL-17 cytokines signaling. We
also demonstrated a requirement for CIKS-mediated signaling
in a glomerular basement membrane (GBM) antibody-induced
model of glomerulonephritis, providing further evidence for a
direct role of IL-17 cytokines ‘‘downstream’’ of autoantibodies.
These findings identify IL-17 cytokines and the CIKS signaling
adaptor as potential therapeutic targets in lupus nephritis.
RESULTS
Loss of the IL-17 Receptor Adaptor CIKS Improves
Survival of Fcgr2b–/– Mice
We first examined IL-17 cytokine expression in the Fcgr2b/
mice at or shortly after the onset of pathology at about 6 months
of age. We detected an increased number of IL-17(A) and IL-17F
producers among CD3+ T cells, especially in lymph nodes, and
to a lesser extent spleens (Figures 1A and 1B; see also Figure S1unity 37, 1104–1115, December 14, 2012 ª2012 Elsevier Inc. 1105
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Figure 2. CIKS Contributes to Germinal Center Formation in Fcgr2b–/– Mice
(A and B and D and E) Flow cytometric analysis of spleen cells of WT, Fcgr2b/.Traf3ip2+/, and Fcgr2b/.Traf3ip2/ mice. Representative staining profiles
and percentages of (A and B) germinal center B cells (CD19+GL7hiFAShi) and (D and E) plasma cells (B220loCD138+) are shown.
(C) Immunofluorescence staining of spleen sections for IgD (green) and CD35 (red) expression. Scale bar = 100 mm.Data are representative of fivemice per group.
(F and G) Representative histogram (F) and mean fluorescence intensity (MFI) (G) for H2-Ab1 on CD19+ cells (*p < 0.05, **p < 0.01, ***p < 0.001; mean ± SEM;
n = 7–9).
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Roles of IL-17 Cytokines in Lupus Nephritisavailable online). The fraction of CD4CD8CD3+ (double-nega-
tive, DN-T) cells was specifically increased in lymph nodes,
a population reportedly expanded in SLE patients and a lupus
mouse model (Crispı´n et al., 2008; Kyttaris et al., 2010) (Figures
1C and 1D). We observed significant increases in IL-17A and/or
IL-17F producing CD4+ T cells (Th17 cells) in spleens and IL-17A
and/or IL-17F producing DN-T cells in lymph nodes (Figures 1E
and 1F; there was also a trend toward an increase in Th17 cells
in lymph nodes). The IL-17-producing DN-T cell population in
lymph nodes included gd+ and ab+ T cells, but not invariant
natural killer T (iNKT) cells (Figure S1).
Next we asked whether IL-17 cytokines play a critical role in
the fatal outcome in this lupus model. We crossed Fcgr2b/
mice with Traf3ip2/ C57BL/6 mice to generate doubly defi-
cient mice (Fcgr2b/.Traf3ip2/) and littermate controls
deficient in Fcgr2b and heterozygous for Traf3ip2 (Traf3ip2
heterozygosity did not alter phenotypes of wild-type [WT] or
Fcgr2b/ mice). Mice were followed for up to 12 months of
age, at which time just 7.7% (1 of 13) of Fcgr2b/were still alive,
whereas 75% (9 of 12) of Fcgr2b/.Traf3ip2/ mice had
survived (Figure 1G; an 89.7% improvement of survival rates).
This significant difference in survival suggests that Traf3ip2
(CIKS) plays an important role in development of fatal lupus
pathology in the Fcgr2b/ mice.
CIKS Contributes to Germinal Center Formation in
Fcgr2b–/– Mice
Unlike WT mice, Fcgr2b/ mice readily formed spontaneous
germinal centers and expanded their plasma cell numbers;
however, in mice also lacking Traf3ip2 these phenotypes were
substantially, though not completely, reversed (Figures 2A–
2E; Figure S2). We also assayed for preswitched (germline)1106 Immunity 37, 1104–1115, December 14, 2012 ª2012 Elsevier Inand postswitched immunoglobulin transcripts with semi-
quantitative RT-PCR to confirm these findings (Figure S2).
We noted increased expression of MHC class II (H2-Ab1) on
B cells in Fcgr2b/ mice, and this expression was sig-
nificantly reduced in mice also lacking Traf3ip2 (Figures 2F
and 2G). Together, these results suggest that IL-17 cyto-
kines signaling via CIKS (Traf3ip2) contribute to spontaneous
germinal center B cell formation, plasma cell development,
and MHC class II expression on B cells in lupus-prone
Fcgr2b/ mice.
Loss of CIKS in B Cells Does Not Block Development
of Glomerulonephritis
To determine whether IL-17 cytokines directly targeted B cells
to promote formation of spontaneous germinal centers in
Fcgr2b/ mice and to cause disease, we generated mice in
which Traf3ip2 was conditionally deleted in B cells with Mb1-
driven Cre recombinase (Figure S3; Fcgr2b/.Traf3ip2fl/fl-Mb1).
Although loss of Traf3ip2 in B cells of Fcgr2b/ mice clearly
reduced splenomegaly and total number of B cells and GC
B cells, it did not significantly reduce the percentage of GC
B cells or plasma cells, although there was a trend toward lower
numbers (Figures 3A and 3B; Figure S3). Expression of H2-Ab1
on B cells of Fcgr2b/.Traf3ip2fl/fl/Mb1 mice was reduced
compared to Fcgr2b/.Traf3ip2wt/flmice. Importantly, however,
Fcgr2b/ mice lacking Traf3ip2 in B cells still developed
glomerulonephritis comparable to Traf3ip2 sufficient Fcgr2b/
mice (Figures 3D and 3E). Thus CIKS (Traf3ip2)-mediated sig-
naling by IL-17 cytokines in B cells in Fcgr2b/ mice promotes
the overall increase in spleen size and total number of B cells but
is not required for the increased percentage of GC B cells or for
development of glomerulonephritis.c.
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Figure 3. Loss of IL-17 Cytokine Signaling in B Cells Does Not Block Development of Glomerulonephritis
(A) Flow cytometric analysis of splenocytes of WT, Fcgr2b/.Traf3ip2wt/fl, and Fcgr2b/.Traf3ip2fl/fl-Mb1 mice, showing percentage and total numbers of
CD19+GL7hiFAShi (GC B cells). (*p < 0.05, ***p < 0.001; mean ± SEM; n = 9–11).
(B) Immunofluorescence staining of spleen sections for IgD (green) and CD35 (red) expression. Scale bar = 100 mm. Data representative of five mice per group.
(C) Representative histogram and mean fluorescence intensity (MFI) for H2-Ab1 on CD19+ cells (*p < 0.05; mean ± SEM; n = 9–11).
(D) Upper panels show H&E staining (403) showing increased glomerular hypercellularity in kidney sections of Fcgr2b/.Traf3ip2wt/fl and Fcgr2b/.
Traf3ip2fl/fl-Mb1mice (6–8 months old). Lower panels show PAS staining (40X) showing increased numbers of intracapillary leukocytes and double contours of the
glomerular basement membrane in kidney sections of Fcgr2b/.Traf3ip2wt/fl and Fcgr2b/.Traf3ip2fl/fl-Mb1 mice. Data are representative of 8–10 mice per
group. Scale bar = 50 mm.
(E) Glomerular scores and interstitial scores of Fcgr2b/.Traf3ip2wt/fl and Fcgr2b/.Traf3ip2fl/fl-Mb1 mice (mean ± SEM; n = 8–10).
Immunity
Roles of IL-17 Cytokines in Lupus NephritisCIKS-Mediated Signaling Is Not Required for
Autoantibody Production but Is Critical for End-Organ
Pathology in Fcgr2b–/– Mice
Despite reduced numbers of spontaneous germinal centers and
splenic plasma cells in Fcgr2b/.Traf3ip2/ as compared
to Fcgr2b/.Traf3ip2+/ littermates, the titers and staining
patterns for anti-nuclear antibodies (ANA) did not differ (Figures
4A and 4B). Similarly, we did not observe any reduction in
double-stranded DNA (dsDNA) IgG antibodies (regardless of
isotype), nRNP antibodies, total serum IgG or IgG deposition
in kidneys in the absence of Traf3ip2 in Fcgr2b/mice (Figures
4C and 4D; Figure S4). However, dsDNA antibody amounts do
not always correlate with the clinical activities of lupus nephritis
(Christensen et al., 2005; Mok, 2010). Indeed, mice deficient in
Traf3ip2 exhibited markedly reduced infiltration of inflammatory
cells into kidneys (Figure 4E). Glomerular pathology was greatly
ameliorated in Traf3ip2 deficient Fcgr2b/ mice as visualized
in H&E and PAS stained sections (Figures 4F and 4G) andImmquantified as glomerular and interstitial scores (Figures 4H
and 4I).
Our results suggest that although signaling of IL-17 cytokines
via CIKS was able to promote formation of germinal centers in
Fcgr2b/mice, this was not critical for autoantibody production
or IgG deposition. Autoantibody production in this Fcgr2b/
model is likely to be controlled by other factors. IFN-g is reported
to be critical for autoantibody production and IgG deposition in
kidneys of lupus-prone (NZBxNZW)F1 mice as well as for devel-
opment of lupus nephritis (Haas et al., 1998; Peng et al., 1997;
Richards et al., 2001). We observed a significant expansion of
IFN-g producing cells, mainly T cells, in spleens of Fcgr2b/
mice, irrespective of the presence of Traf3ip2 (Figure 4J; Fig-
ure S4). Therefore IFN-g may promote autoantibody production
independent of IL-17 cytokines. These findings suggest that
CIKS-mediated signaling by IL-17 cytokines contributes to the
fatal outcome in this lupus model in a manner separate from
autoantibody formation and IgG deposition.unity 37, 1104–1115, December 14, 2012 ª2012 Elsevier Inc. 1107
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Figure 4. CIKS-Mediated Signaling Is Not Required for Autoantibody Production but Is Critical for End-Organ Pathology in Fcgr2b–/– Mice
(A) Anti-nuclear antibody (ANA) staining of Hep-2 cell coated slides incubated with diluted serum (1:100) from Fcgr2b/.Traf3ip2+/ and Fcgr2b/.Traf3ip2/
mice. Data are representative of ten mice per group. Scale bar = 50 mm.
(B) ANA titers; shown are final dilution factors of serum still ANA positive (mean ± SEM; n = 10).
(C) ELISA assays for dsDNA IgG (mean ± SEM; n = 7–10).
(D) Immunofluorescence staining for IgG deposition in kidney sections from Fcgr2b/.Traf3ip2+/ and Fcgr2b/.Traf3ip2/ mice. Data are representative of
7 or 8 mice per group. Scale bar = 50 mm.
(E) H&E staining of kidney sections (20X) showing substantial leukocyte infiltration in the interstitium of Fcgr2b/.Traf3ip2+/ but not Fcgr2b/.Traf3ip2/mice.
Scale bar = 100 mm.
(F) H&E staining (40X) showing glomerular hypercellularity with intracapillary proliferation, and periglomerular leukocyte infiltration in kidney sections of
Fcgr2b/.Traf3ip2+/, but not Fcgr2b/.Traf3ip2/ mice (6–8 months old).
(G) PAS staining (40X) showing increased numbers of intracapillary leukocytes and double contours of the glomerular basement membrane in
Fcgr2b/.Traf3ip2+/ but not Fcgr2b/.Traf3ip2/ mice. Data are representative of 7–10 mice per group. Scale bar = 50 mm.
(H and I) Glomerular scores and interstitial scores of Fcgr2b/.Traf3ip2+/ and Fcgr2b/.Traf3ip2/ mice (*p < 0.05, **p < 0.01; mean ± SEM; n = 7–10).
(J) Percentage of IFN-g producing cells from splenocytes evaluated by flow cytometry (*p < 0.05; mean ± SEM; n = 5–7).
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Roles of IL-17 Cytokines in Lupus NephritisWe also observed increases in CD11b+CD11c monocytic
cells, CD11b+CD11c+ myeloid DCs (mDCs), and CD11c+B220+
plasmacytoid DCs (pDCs) in spleens from Fcgr2b/ mice;
notably, these increases were reversed in the absence of
Traf3ip2. Furthermore the shift toward increased numbers of T
effector-memory cells (CD4+CD62LCD44+) in this lupus model
was partially reversed in the absence of CIKS (Figure S4). There-
fore, CIKS-mediated signaling by IL-17 cytokines in Fcgr2b/
mice promotes increases in numbers of monocytic cells,
mDCs, and pDCs and contributes to activation and/or differenti-
ation of T cells. These latter systemic changes could have had
a role in initiating kidney pathology but could also have occurred
as a consequence thereof.
Loss of IL-17A Does Not Reduce Formation of
Spontaneous Germinal Centers but Does Protect
against Fatal Glomerulonephritis in Fcgr2b–/– Mice
The CIKS adaptor is not only required for signaling by IL-17 but
also other members of this cytokine family (Chang et al., 2011;1108 Immunity 37, 1104–1115, December 14, 2012 ª2012 Elsevier InGaffen, 2009). We crossed Fcgr2b/ mice with Il17a/ mice
to determine whether IL-17 and/or other members of this family
might be critical for the pathogenesis in this lupus model.
Although only 35.7% (5 of 14) of Fcgr2b/.Il17a+/ mice were
alive after 12 months, this number increased to 91.7% (11
of 12) of Fcgr2b/.Il17a/ littermates (Figure 5A; a 61.1%
improvement of survival rates). This suggests that IL-17(A) plays
an important, albeit not exclusive role in the CIKS-dependent
fatal outcome of Fcgr2b/ mice. (Fcgr2b/.Il17a+/ mice
were somewhat less susceptible to lupus pathology, most likely
due to a subtly different BL6 background of Il17a/ mice;
there was no apparent difference between Fcgr2b/.Il17a+/+
and Fcgr2b/.Il17a+/ mice). The protection afforded by loss
of Il17a also failed to correlate with any reduction in ANA or
dsDNA antibodies (Figures 5B and 5C). Unexpectedly, Il17a defi-
cient mice failed to show any reduction in the spontaneous
germinal centers that developed in Fcgr2b/ mice (Figure 5D;
Figure S5). Consistent with this, immunoglobulin isotype switch-
ing, numbers of plasma cells, and H2-Ab1 expression on B cellsc.
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(A) Cumulative survival of Fcgr2b/.Il17a+/ mice (n = 14) and Fcgr2b/.Il17a/ mice (n = 12); (***p < 0.001). Percent survival rate change = ([% survival of
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(B) ANA staining of Hep-2 cell coated slides incubated with diluted serum (1:100) from Fcgr2b/.Il17a+/, and Fcgr2b/.Il17a/mice. Data are representative
of 10 mice per group. Scale bar = 50 mm.
(C) ELISA assays for dsDNA IgG (mean ± SEM; n = 11).
(D) Representative flow cytometric staining profile for germinal center B cells (CD19+GL7hiFAShi) from mice as shown; data representative of ten mice per group.
Immunofluorescence staining of spleen sections for IgD (green) and CD35 (red) expression. Scale bar = 100 mm. Data are representative of five mice per group.
(E) Upper panels show H&E staining (40X) showing glomerular hypercellularity with intracapillary proliferation in kidney sections of Fcgr2b/.Il17a+/ but not
Fcgr2b/.Il17a/mice (10–12months old). Lower panels show PAS staining (40X) showing increased numbers of intracapillary leukocytes and double contours
of the glomerular basement membrane in kidney sections of Fcgr2b/.Il17a+/ but not Fcgr2b/.Il17a/mice. Data are representative of 7–9 mice per group.
Scale bar = 50 mm.
(F) Glomerular and interstitial scores of Fcgr2b/.Il17a+/ and Fcgr2b/.Il17a/ mice (**p < 0.01; mean ± SEM; n = 7–9).
Immunity
Roles of IL-17 Cytokines in Lupus Nephritisin the Fcgr2b/ mice were not changed in the absence of Il17a
(Figure S5). Because expression of IL-17B or IL-17C did not
change in spleens of Fcgr2b/mice compared toWTmice (Fig-
ure S5), the increased amounts of IL-17F likely compensated for
loss of IL-17A (Figures 1A and 1B; Figure S5), although this
remains to be formally proven.
The fact that the survival of Fcgr2b/ mice was significantly
improved in the absence of IL-17, while spontaneous germinal
center formation and autoantibody production continued
unabated, strongly points to a critical and likely direct role for
IL-17-mediated signaling in fatal end-organ pathologies. Consis-
tent with this hypothesis, loss of Il17a significantly reduced
inflammatory cell infiltration and glomerulonephritis in kidneys
of Fcgr2b/ mice (Figures 5E and 5F).
Loss of CIKS or IL-17A Prevents Recruitment of
Inflammatory Cells into Kidneys of Fcgr2b–/– Mice
We investigated which, if any, of the potential IL-17-producing
T cell subsets could be detected in perfused kidneys ofImmFcgr2b/ mice. We noted significant increases in numbers of
DN-T and CD4+ T cells and, to a lesser degree, CD8+ T cells in
kidneys of Fcgr2b/ mice (Figure 6A). Surprisingly, loss of
Traf3ip2 reversed the numbers of DN-T cells (Figure 6A). In
contrast, the fraction of DN-T cells in lymph nodes did not
change in the absence of Traf3ip2, suggesting that IL-17 cyto-
kines might play a role in recruitment and/or maintenance of
these cells in kidneys (Figure 6B).We also performed intracellular
staining of cells isolated from kidneys and found that both DN-T
cells andCD4+ T cells produced IL-17 (Figure S6). Nextwe tested
for expression of IL-17 cytokines in kidneys of Fcgr2b/ mice.
We detected a significant increase in IL-17 as well as IL-17C,
but not IL-17F or IL-17B messenger RNA (mRNA) expression in
Fcgr2b/ mice (Figure 6C). Preferentially increased expression
of IL-17 is consistent with the fact that loss of this cytokine
afforded significant protection (Figure 5A). Nevertheless, since
loss ofTraf3ip2 improved survival rates of Fcgr2b/ mice more
than loss of Il17a (89.7% versus 61.1%), it is likely that IL-17C
also contributed to kidney pathology (see Discussion).unity 37, 1104–1115, December 14, 2012 ª2012 Elsevier Inc. 1109
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Figure 6. Loss of CIKS or IL-17A Prevents Recruitment of Inflammatory Cells into Kidneys of Fcgr2b–/– Mice
(A) Flow cytometric analysis of cells isolated from kidneys of WT, Fcgr2b/.Traf3ip2+/ and Fcgr2b/.Traf3ip2/ mice, showing numbers of CD3+, CD3+
CD4CD8 (DN-T), CD3+CD4+, and CD3+CD8+ cells (*p < 0.05, **p < 0.01; mean ± SEM; n = 13).
(B) Percentage of DN-T (CD3+CD4CD8) in LNs of mice as shown (mean ± SEM; n = 5–8).
(C) Fold change in relative mRNA expression of Il17a, Il17f, Il17b, and Il17c in kidneys of WT and Fcgr2b/ mice (*p < 0.05, **p < 0.01; mean ± SEM; n = 4–5).
(D and E) Representative staining profiles of cells isolated from kidneys of WT, Fcgr2b/.Traf3ip2+/, and Fcgr2b/.Traf3ip2/ mice showing (D) neutrophils
(Ly6g+Ly6c+) and (E) inflammatory monocytes (CD11b+F4/80lo) and macrophages (CD11b+F4/80hi) after gating on Ly6c+Ly6g cells. Data are representative of
13 mice per group.
(F) Immunofluorescence of kidney sections from Fcgr2b/.Traf3ip2+/ and Fcgr2b/.Traf3ip2/ mice (6–8 months old) or Fcgr2b/.Il17a+/ and
Fcgr2b/.Il17a/ mice (10–12 months old) stained with anti-IgG (green), anti-7/4 (red), and anti-Ly6g (blue) to identify immune complexes, inflammatory
monocytes and macrophages (7/4+Ly6g), and neutrophils (7/4+Ly6g+).
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Immunity
Roles of IL-17 Cytokines in Lupus NephritisWe detected increased numbers of neutrophils (Ly6g+Ly6c+)
and monocytic cells (Ly6c+Ly6g CD11b+F4/80lo) in perfused
kidneys of Fcgr2b/ mice; by contrast, these increases were
largely erased in the absence of Traf3ip2 or Il17a (Figures 6D
and 6E; Figure S6). However, although the absence of Traf3ip2
in this lupus model largely prevented the increase in DN-T cells,
this was not the case in mice lacking Il17a (Figure S6); therefore
IL-17C could have had a role in recruitment and/or maintenance
of these cells in kidneys. To determine the anatomical locations
of infiltrating myeloid cells in kidneys of Fcgr2b/ mice, and to
confirm the absence of such cells in mice lackingTraf3ip2 and
Il17a, we stained tissue sections of kidneys for neutrophils
(7/4+Ly6g+), monocytes and macrophages (7/4+Ly6g) (Daley
et al., 2008; Rosas et al., 2010), and for IgG deposition. We
observed substantial foci of infiltrating neutrophils and mono-
cytic cells in Fcgr2b/ mice; infiltration of these cells extended
into interstitial regions. Loss of either Traf3ip2 or Il17a largely
prevented infiltration of these cells, while IgG deposition re-
mained (Figure 6F).
Next we examined whether CIKS-mediated signaling
might contribute to increased expression of neutrophil- and
monocyte-attracting chemokines in kidneys of Fcgr2b/ mice.
We observed CIKS (Traf3ip2)-dependent increases in Cxcl1,
Cxcl5, Ccl2, and TNF-a and to a lesser extent Ccl20 mRNA
expression (Figure 6G); TNF-a is known to strongly synergize
with IL-17 (Hartupee et al., 2007). We extended these analyses
to kidney biopsies from lupus nephritis patients and found foot-
prints of IL-17 cytokines and TNF-a in these samples, suggesting
that our findings may be relevant for development of lupus
nephritis in patients (Figure S6).
Increased ability to form pathogenic neutrophil extracellular
traps (NETs) and impairment in their degradation have been
associated with lupus nephritis in humans (Hakkim et al.,
2010). To test whether neutrophils recruited into kidneys of
Fcgr2b/ mice might develop NETs in tissue, we performed
immunofluorescence staining and detected NETs in kidneys of
Fcgr2b/ mice, but not in mice also deficient in Traf3ip2
(Figure 6H).
These results indicate that CIKS-mediated signaling by IL-17
cytokines in kidneys of Fcgr2b/mice is involved in recruitment
of DN-T cells, monocytic cells as well as neutrophils, with the
latter cells able to form pathogenic NETs. These findings may
explain the role of these cytokines in the development of fatal
end-organ pathology.
CIKS Deficiency Protects Mice from the Development of
Glomerular Basement Membrane Antibody-Induced
Glomerulonephritis
The data suggest a critical role for CIKS-mediated signaling by
IL-17 cytokines in development of glomerulonephritis, appar-
ently acting downstream of autoantibodies. To directly test
whether IL-17 cytokines can contribute to the pathogenic effects
of autoantibodies, we challenged CIKS sufficient and deficient
mice with glomerular basement membrane antibodies in an(G) Relative mRNA expression (normalized by actin) of Cxcl1, Cxcl5, Ccl2
Fcgr2b/.Traf3ip2/ mice (*p < 0.05, **p < 0.01; mean ± SEM; n = 6–8).
(H) Immunofluorescence of kidney sections (genotypes as indicated), stained with
representative of 4–6 mice per group.
Immestablished model of accelerated nephrotoxic nephritis that is
associated with glomerular damage (Vielhauer et al., 2005).
Although IL-17 has been proposed to have a pathogenic role in
similar models, it has also been suggested to have a protective
role (Odobasic et al., 2011; Paust et al., 2012). We found an
increase in expression of Il17a, but not Il17c or Il17f in kidneys
of WT mice after treatment with CFA and GBM antibodies
(Figure S7). The numbers of neutrophils, monocytes, andmacro-
phages were also increased; by contrast, Traf3ip2-deficient
mice showed significantly lower counts of neutrophils and
monocytes and a trend toward lower counts of macrophages
(Figures 7A–7D). These findings correlated well with decreased
renal pathology scores (Figures 7E–7G) and inflammatory cell
infiltrations (Figures 7H and 7I) inTraf3ip2-deficient mice. Of
note, we only detected an increase in CD4+ but not DN-T cells
in kidneys in this model (Figure S7). These data demonstrate
that CIKS-mediated signaling is essential for disease in a model
of anti-GBMmediated glomerulonephritis. This finding is consis-
tent with a major role for IL-17 cytokines in renal injury at a step
downstream of autoantibody production.
DISCUSSION
Increased amounts of IL-17 in serum of SLE patients have been
correlated with disease activity; in addition, increased produc-
tion of IL-17 is prominent in two mouse models of lupus (Hsu
et al., 2008; Kozyrev et al., 2008; Nalbandian et al., 2009). As
shown here, elevated expression of IL-17 was also observed in
lupus-prone Fcgr2b/ mice, in particular in lymph nodes and
kidneys. Beyond these observations, however, the work pre-
sented establishes that IL-17 cytokines and their signaling via
the adaptor Traf3ip2 (CIKS, Act1) play critical roles in the
ultimately fatal outcome in a lupus disease model: loss of Il17a
or Traf3ip2 profoundly improved survival in Fcgr2b/ mice,
correlating with greatly ameliorated kidney pathology.
Lack of Traf3ip2 in Fcgr2b/mice afforded greater protection
than lack of Il17a (89.7% versus 61.1% improvement in survival
rates, respectively). Although this could be due to slight genetic
background differences, it is more likely that in addition to major
contributions from IL-17, IL-17C too may have played a role,
given that it also signals via CIKS (Chang et al., 2011; Gaffen,
2009) and given that its expression was significantly increased
in kidneys of Fcgr2b/ mice as well. Alternatively, it remains
at least theoretically possible that CIKS could have made contri-
butions independent of IL-17 cytokines (Valente et al., 2012).
Although absence of CIKS led to reduced spontaneous
germinal center formation in this model, surprisingly, lack of
this adaptor (or of IL-17) did not lead to a noticeable reduction
in ANA, dsDNA antibodies, or immunoglobulin deposition in
kidneys. Aside from germinal centers, autoantibodies could
also have arisen from extrafollicular B cells (Sweet et al., 2010).
Importantly, loss of Il17a or Traf3ip2 did prevent the influx of
inflammatory myeloid-derived cells into kidneys of Fcgr2b/
mice. Therefore, the present model allowed us to separate, Ccl20, and TNF-a in kidney tissues of WT, Fcgr2b/.Traf3ip2+/, and
anti-MPO (green), anti-LL37 (red), and DAPI (blue). Scale bar = 50 mm. Data are
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Figure 7. CIKS Deficiency Protects Mice from the Development of Antibody-Induced Glomerulonephritis
(A) Representative staining profiles of cells isolated from kidneys of WT and Traf3ip2/ mice showing neutrophils (Ly6g+Ly6c+). Data are representative of ten
mice per group.
(B–D) Flow cytometric analysis of infiltrating cells in kidneys of WT and Traf3ip2/ mice showing (B) neutrophils (Ly6g+Ly6c+), (C) inflammatory monocytes
(Ly6c+Ly6g CD11b+F4/80lo) and (D) macrophages (Ly6c+Ly6g CD11b+F4/80hi). (*p < 0.05, **p < 0.01; mean ± SEM; n = 10).
(E–G) Histology scores showing percentage of (E) abnormal glomeruli, (F) crescent, and (G) interstitial scores of WT and Tra3ip2/mice (**p < 0.01, ***p < 0.001;
mean ± SEM; n = 10).
(H and I) H&E staining (H) showing inflammatory cell infiltration in kidney sections of WT but not Traf3ip2/ mice. PAS staining (I) showing glomerular hyper-
cellularity, glomerular deposition of PAS stainedmaterial, and crescentric glomerunlonephritis ofWT but not Traf3ip2/mice. Data are representative of tenmice
per group. Scale bar = 50 mm.
Immunity
Roles of IL-17 Cytokines in Lupus Nephritispotential inputs of IL-17 cytokines to autoantibody production
from other, more direct contributions of these cytokines to
kidney pathology. In further support of a critical local role of
IL-17 cytokines in kidney disease, we demonstrated local
production of IL-17 by infiltrating Th17 and DN-T cells, and of
IL-17C, most likely by epithelial cells; in addition, we detected
increased expression of TNF-a, known to synergize with IL-17
cytokines (Hartupee et al., 2007). The presence of these cyto-
kines may represent a primary means for attracting inflammatory1112 Immunity 37, 1104–1115, December 14, 2012 ª2012 Elsevier Incells into kidneys via induced expression of chemoattractant
genes such as Cxcl1, Cxcl5, Ccl2, and Ccl20 (Ramirez-Carrozzi
et al., 2011; Ruddy et al., 2004; Shahrara et al., 2010).
Only loss of Traf3ip2, but not Il17a, notably reduced sponta-
neous germinal center formation. Given that we observed
elevated amounts of IL-17F, but not IL-17B or IL-17C in spleens
of Fcgr2b/ mice, it is reasonable to suggest that IL-17F could
have compensated for lack of IL-17 to promote spontaneous
germinal center formation. Loss of Traf3ip2 in B cells largelyc.
Immunity
Roles of IL-17 Cytokines in Lupus Nephritisreversed increases in spleen size, total GC B cells, and MHC
Class II expression on B cells, but not the propensity of B cells
to form germinal centers in spleens of Fcgr2b/mice, suggest-
ing that IL-17 cytokines may also affect B cells indirectly.
Loss of IL-17RA in BXD2 mice caused definite reductions in
autoantibodies and immunoglobulin deposition; in contrast, the
absence of CIKS in Fcgr2b/ mice did not, although sponta-
neous germinal center formation was reduced in both contexts.
It is not clear why production of autoantibodies wasmore depen-
dent on IL-17 cytokines in the BXD2model than in the Fcgr2b/
model. It has been reported that IFN-g production is critical for
autoantibody production in lupus-prone (NZBxNZW) F1 mice
(Haas et al., 1998), and expression of this cytokine was elevated
in Fcgr2b/mice, independent of IL-17 cytokine signaling; thus,
IFN-g may have been responsible for autoantibody production.
The local production of IL-17 in kidneys of Fcgr2b/ mice
from both CD4+ T cells and DN-T cells was likely instrumental
in recruitment of neutrophils and monocytes, and thus the
ensuing inflammation. The mechanisms leading to local IL-17
production remain to be determined. Interestingly, kidney infil-
tration of DN-T cells was dependent on CIKS-mediated sig-
naling, but not IL-17, suggesting the possibility that IL-17C
may have targeted these cells to exacerbate an already initiated,
IL-17-dependent inflammatory process in Fcgr2b/ mice.
IL-17C has also been reported to enhance IL-17 production
from infiltrating CD4+ T cells (Chang et al., 2011). Our data
suggest that local production of IL-17 cytokines is critical for
kidney pathology, consistent also with the observation that
CIKS was required for glomerulonephritis and recruitment of
neutrophils and monocytes into kidneys in the GBM antibody-
induced model of glomerulonephritis. Of note, whereas CD4+
T cells numbers and Il17a expression were elevated in kidneys
of Fcgr2b/ mice and GBM antibody-treated mice, DN-T cells
and Il17c were only elevated in Fcgr2b/ mice.
Prior reports have suggested that the presence of IL-
17-producing Th17 and DN-T cells in kidneys of SLE patients
and in the MRL/lpr and B6/lpr mouse models (Crispı´n et al.,
2008; Zhang et al., 2009). Consistent with this, IL-23 receptor
deficiency in B6/lpr mice mitigates glomerulonephritis in that
model (Kyttaris et al., 2010). However, IL-23 is known to stabilize
pathogenic Th17 cells and thus boost expression of not only
IL-17 but also several other cytokines, including IFN-g (Opp-
mann et al., 2000); furthermore, it can restrain regulatory T cell
activity (Izcue et al., 2008). Indeed, loss of the IL-23 receptor in
B6/lpr mice reduces autoantibody production and immune
complex deposition in kidneys (Kyttaris et al., 2010). The present
findings directly demonstrate the importance of specifically
IL-17 cytokines in the development of fatal kidney pathology,
likely including IL-17C, the expression of which is not known to
be controlled by IL-23.
Our studies identify IL-17 cytokines and the CIKS-mediated
signaling pathway as potential therapeutic targets in SLE, espe-
cially in lupus nephritis, and also in anti-GBM disease. Biologic
therapies directed at B cells in mice and patients have met
with limited success, especially in more severe cases of lupus
nephritis (Navarra et al., 2011; Sanz and Lee, 2010); thus, there
is great need for new treatment options. The present findings
validate IL-17 cytokines andCIKS as promising targets. Because
these cytokines have also been implicated in other localImminflammatory conditions, including RA, MS, and psoriasis,
therapies targeting them or their signaling pathways may have
wide-ranging benefits.
EXPERIMENTAL PROCEDURES
Mice
Traf3ip2/, Fcgr2b/, Il17a/, and Mb1-cre mice have been described
(Claudio et al., 2009; Hobeika et al., 2006; Nakae et al., 2002; Takai et al.,
1996). Mice were intercrossed to generate animals with compound deficiency
of Fcgr2b and Traf3ip2, Fcgr2b and Il17a, and control littermates. To generate
Traf3ip2 floxed mice, exon 2 was flanked by loxP sites (Ozgenes, Australia)
(Figure S3). WT/Flox mice were crossed with Mb1-cre mice to generate
mice with B cells specific Traf3ip2 deletion. The experimental mice were
used at the age of 6–8 months (Fcgr2b/.Traf3ip2 strain) and 10–12 months
(Fcgr2b/.Il17a strain). Mice were bred and housed in a facility at the National
Institute of Allergy and Infectious Diseases (NIAID), and all experiments were
performed with the approval of the NIAID Animal Care and Use Committee
and in accordance with all relevant institutional guidelines.
Glomerular Basement Membrane Antibody Induced
Glomerulonephritis
The protocol for GBM Ab-induced glomerulonephritis has been described
(Rosenkranz et al., 1999; Vielhauer et al., 2005). Briefly, mixed rabbit IgG at
a final concentration of 0.1 mg/ml in CFA (2.5 mg/ml) was injected subcutane-
ously on day3, and then heat inactivated anti-GBM serumwas intravenously
injected (100 ml) via tail vein on day 0. The 8- to 10-week-old mice were
followed up and sacrificed to collect tissues for analysis on day 14.
Cellular Analysis
Splenocytes were isolated as previously described (Pisitkun et al., 2010)
and stained with the following antibodies: B220(RA3-6B2), GL7(Ly-77),
FAS(Jo2), CD138(281-2), IgM(II/41), IAb(AF6-120.1), CD4(L3T4), CD44(IM7),
CD11b(M1/70), Ly6c(AL-21), CD3e(145-2C11), CD11c(HL3), and CD62L(Ly-
22) (BD Biosciences); CD19(eBio1D3), ICOS(7E.17G9), F4/80(BM8), CD8a
(53-6.7), and IL17A(eBio17B7) (eBioscience); Ly6g (IA8) (Biolegend), CD1d-
tetramer(PBS57) (NIH tetramer facility), and Aqua (Invitrogen). Cells were
stimulated with PMA (5 ng/ml), Ionomycin (500 ng/ml), and Golgi stop (BD)
for 4 hr before intracellular staining. Data were collected with a FACSCanto
instrument (BD Biosciences).
In Vivo Immunoglobulin Isotype Switching
B cells were isolated from splenocytes using anti-CD19 beads (Miltenyi). RNA
isolation from B cells and complimentary DNA (cDNA) synthesis were per-
formed as described (Pisitkun et al., 2010). RT-PCR for immunoglobulin
transcription was performed by using primers and condition as described
(Muramatsu et al., 2000).
Autoantibody Analysis
Anti-nuclear antibodies (ANA) were assayed with Hep-2 cells (BION). Slides
were mounted with Vectashield (Vector Labs) and visualized using a fluores-
cence microscope. Mouse dsDNA IgG was detected by ELISA using the
dsDNA IgG kit (5120) (Alpha Diagnostic International).
Histological Analysis
Kidneys were fixed in 4% paraformaldehyde. Tissue sections were stained
with H&E or Periodic acid–Schiff (PAS) and visualized by Olympus BX50.
Histological scores were evaluated as described (Chan et al., 1997). We
analyzed kidney pathology from these mice compared to their control litter-
mates at between 6–8 months (Fcgr2b/.Traf3ip2/) and 10–12 months
(Fcgr2b/.Il17a/) of age. In GBM induced glomerunlonephritis, the
histology scores were determined as described (Odobasic et al., 2011).
Immunofluorescence
Frozen sections (5 mm thickness) were fixed in acetone, and blocked with 1%
BSA in PBS. Diluted antibodies were incubated for 1 hr. Endogenous biotin
was blocked using Streptavidin-Biotin blocking kit (Vector Labs). The followingunity 37, 1104–1115, December 14, 2012 ª2012 Elsevier Inc. 1113
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Roles of IL-17 Cytokines in Lupus Nephritisantibodies were used: IgD(11-26c.2a) and CD35(8C12) (BD Biosciences),
IgG(A11029, Invitrogen), 7/4(Cedarlane), Ly6g(IA8, Biolegend), MPO(2D4,
Abcam), and LL37(LS-B2687 CAMP, LS Biosciences). Slides were mounted
with Vectashield with or without DAPI (Vector Labs) and visualized using a
Leica AF6000LX fluorescence microscope.
Isolation of Single Cells from the Kidney for FACS Analysis
Isolation of single cells from the kidneys was modified from a described
procedure (Gunaratne et al., 2010). In brief, perfusion of the kidneys was
performed with 20 ml of prewarmed HBSS while the mice were anesthesized
with Avertin (0.4–0.75 mg/g of body weight). The perfused kidneys were
digested with collagenase B (0.230 U/ml) (Roche Diagnostics) in 10% FCS in
IMEM for 20 min (37C). Single cells of kidneys were isolated the same way
as splenocytes (see above) and cell suspensions were subjected to density
separation to eliminate the epithelial or tubular cells of the kidneys using
Lympholyte-M (Cedarlane).
Quantitative Real-Time PCR Analysis
RNA was purified using TRIzol (Invitrogen), cDNA synthesis, and quantitative
real-time PCR was performed as described (Pisitkun et al., 2010). Control
RNA of human kidneys was purchased from Ambion, Agilent, and Origene
(CR560857, CR560624). The mouse or human primers (Taqman) for actin,
IL-17, IL-17F, IL-17C, IL-17B, TNF-a, CXCL1, CXCL5, CCL2, and CCL20
were obtained from Applied Biosystems.
Statistical Analysis
Gehan-Breslow-Wilcoxon test was performed with GraphPad Prism 5 to
determine statistical significance of survival curves. Student’s t test (one-
tailed) was used for other comparisons.
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